The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.

The protein c-erbB-2, also known as Her2/neu, is a prognostic breast cancer marker assayed in tissue biopsies from women diagnosed with malignant tumors. Present studies suggest that soluble fragments of the c-erbB-2 oncogene may be released from the cell surface and become detectable in patients with carcinoma of the breast. Consequently, the purpose of this study was to assay the c-erbB-2 protein in the saliva and serum of women with and without carcinoma of the breast and to determine whether the protein possesses any diagnostic value. To determine the diagnostic utility of this oncogene, the soluble form of the c-erbB-2 protein was assayed in the saliva and serum using ELISA in three different groups of women. The three groups consisted of 57 healthy women, 41 women with benign breast lesions, and 30 women diagnosed with breast cancer. To compare the relative diagnostic utility of the c-erbB-2 protein, CA 15-3 was also measured. The CA 15-3 measurements served as a "gold standard" by which to compare the c-erbB-2 protein's diagnostic effectiveness. We found c-erbB-2 protein in the saliva and serum of all three groups of women. The salivary and serological levels of c-erbB-2 in the cancer patients, however, were significantly higher (P < 0.001) than the salivary and serum levels of healthy controls and benign tumor patients. Additionally, the c-erbB-2 protein was found to be equal to or to surpass the ability of CA 15-3 to detect patients with carcinoma. The results of the pilot study suggest that the c-erbB-2 protein may have potential use in the initial detection and/or follow-up screening for the recurrence of breast cancer in women.

[1]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[2]  C. Christensen,et al.  A Comparison of Whole Mouth Resting and Stimulated Salivary Measurement Procedures , 1982, Journal of dental research.

[3]  P. Terrier,et al.  Prognostic importance of low c-erbB2 expression in breast tumors. , 1998, Journal of the National Cancer Institute.

[4]  J. Thigpen,et al.  A Preliminary Study of CA15-3, c-erbB-2, Epidermal Growth Factor Receptor, Cathepsin-D, and p53 in Saliva Among Women with Breast Carcinoma , 2000, Cancer investigation.

[5]  C. Streckfus,et al.  Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women. , 1999, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[6]  M. Pincus,et al.  erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  U. Stenman,et al.  Serum markers for breast cancer. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[8]  I D Mandel,et al.  The diagnostic uses of saliva. , 1990, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[9]  R. Epstein,et al.  Detection of ErbB2 o versignalling in a majority of breast cancers with phosphorylation-state-specific antibodies , 1999, The Lancet.

[10]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[11]  E. Röttinger,et al.  The value of the tumor marker CA 15‐3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen , 1991, Cancer.

[12]  J. Thigpen,et al.  CA 15–3 and c-erbB-2 presence in the saliva of women , 1999, Clinical Oral Investigations.

[13]  Á. Ruibal,et al.  Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease , 1989, Cancer.

[14]  M. Pincus,et al.  Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer , 1993 .

[15]  R. Zeillinger,et al.  Tissue expression and serum levels of HER-2/neu in patients with breast cancer. , 1997, Oncology.

[16]  L. Demers,et al.  Serial serum c‐erbB‐2 levels in patients with breast carcinoma , 1996, Cancer.

[17]  O. Kallioniemi,et al.  Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. , 1988, British Journal of Cancer.

[18]  L. Demers,et al.  Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Miyamoto,et al.  Serum c-erbB-2 in breast cancer patients. , 1994, Acta oncologica.

[20]  B. Dawson-Saunders,et al.  Basic and Clinical Biostatistics , 1993 .

[21]  W Zucchini,et al.  On the statistical analysis of ROC curves. , 1989, Statistics in medicine.